



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 March 2015
EMA/41227/2015
Human Medicines Research and Development Support Division

Public summary of the evaluation of a proposed paediatric investigation plan

Eravacycline for the treatment of complicated intra-abdominal infections and for the treatment of urinary tract infections

On 16 January 2015, the Paediatric Committee of the European Medicines Agency agreed a Paediatric Investigation Plan* (PIP) for eravacycline for the treatment of complicated intra-abdominal infections and for the treatment of urinary tract infections (EMA-001555-PIP01-13).

What is eravacycline, and how is it expected to work?

Eravacycline is not authorised in the European Union. Studies in adults are currently on-going. This medicine is proposed in adults for the treatment of complicated intra-abdominal infection and for the treatment of complicated urinary tract infection.

This medicine is expected to act on the micro-organisms that cause the infection by stopping their protein synthesis, thus blocking their growth and multiplication.

What was the proposal from the applicant?

For children, the applicant proposed: to study the medicine in children from 8 years to less than 18 years of age affected by complicated intra-abdominal infections or complicated urinary tract infections, in a paediatric investigation plan*. The future indications proposed for children are: treatment of complicated intra-abdominal infection and treatment of complicated urinary tract infection. The plan includes the development of a specific pharmaceutical form to be used in children*: tablets of smaller size and with lower content of eravacycline. It also includes a proposal to determine the right dose and to show efficacy and safety of the medicine in non-clinical and clinical studies and to extrapolate data from studies in older children and adults.

The applicant proposed a deferral* for the paediatric clinical studies.

Is there a need to treat children affected by complicated intra-abdominal infections or urinary tract infections?

Taking into account the proposed indication in adults, and the characteristics of the medicine, the Paediatric Committee considered this medicine of potential use for the treatment of complicated intra-



abdominal infections and for the treatment of urinary tract infections. These conditions occur also in children.

What did the Paediatric Committee conclude on the potential use of this medicine in children?

At present, some treatments are available for the treatment of complicated intra-abdominal infections and for the treatment of complicated urinary tract infections in children in the European Union, such as other antibiotics that are known to work. Therefore, the Committee considered that new data are required to decide whether the use of this medicine will bring a benefit to children from 8 years to less than 18 years affected by the condition, and to understand any potential risks.

The Committee considered that there is also a need to develop a specific pharmaceutical form* of this medicine, which would allow to use the medicine safely and accurately in young children, and whose composition* must only include components that are known to be safe in children.

Because there is a need for more medicines for the treatment of the two conditions in children, and this medicine has a potential interest for children, the Committee considered that clinical, extrapolation and modelling and simulation studies were necessary.

The Committee considered that it is more prudent to confirm that the medicine is effective and safe in adults, before starting the paediatric studies.

The Committee agreed with the request of the applicant that the paediatric clinical studies should be deferred, because data on the safety and efficacy of eravacycline in adults are needed to confirm that the medicinal product is safe and efficacious before starting the paediatric clinical studies.

What is the content of the Plan after evaluation?

The Paediatric Committee considered that:

- Studies are not necessary in children from birth to less than 8 years of age because eravacycline is likely to cause staining of the teeth in this population.
- A pharmaceutical form* such as tablets was needed for children aged from 8 years to less than 18 years of age. Tablets of the appropriate size and strength will be developed by the applicant.
- Studies in animals need to be performed, to identify any risk before the medicine is used in young children.
- Determination of the best dose should be done with one trial of the medicine's behaviour in the body and the body's reactions to it.
- It is necessary to study if the medicine is effective to treat the disease in children. This will be done in one study comparing the medicine to active control.
- It is necessary to study the potential side effects of the medicine, to prevent them or to reduce the consequences if they occur. The main concern identified by the PDCO is the potential toxicity of the medicine for testes, bone marrow and teeth (change of colour) and for possible development of hypersensitivity and photosensitivity.
- Partial extrapolation of efficacy/safety is possible in the development of this product, between adults/adolescents and younger children because the mechanism of action is the same in adults and in children and the objective is to reach in children the same levels of medicinal product in the blood that have proven to be effective in adults.

What happens next?

The applicant has now received the EMA Decision (P/0046/2015)* on this medicine. The Decision itself is necessary for the applicant to request in the future a marketing authorisation* for this medicine in adults and/or in children.

The Decision* on the agreed Paediatric Investigation Plan means that the applicant is bound to perform the studies and trials with children in the next months or years. In case of difficulties, or a change in current knowledge or availability of new data, the applicant may request changes to the plan at a later stage. This can be done through a modification of the PIP.

The agreed completion of all the studies and trials included in the Paediatric Investigation Plan is December 2021.

Trials in the Paediatric Investigation Plan will be listed in the public EU Clinical Trials Register (<https://www.clinicaltrialsregister.eu/>) as soon as they have been authorised to be started, and their results will have to be listed in the register within 6 months after they have completed.

The results of the studies conducted in accordance with the agreed Paediatric Investigation Plan will be assessed, and any relevant information will be included in the Product Information (summary of product characteristics, package leaflet). If the medicine proves to be effective and safe to use in children, it can be authorised for paediatric use, with appropriate recommendations on the dose and on necessary precautions. The product information will also describe which adverse effects are expected with the medicine, and wherever possible, how to prevent or reduce these effects.

***Definitions:**

Applicant	The pharmaceutical company or person proposing the Paediatric Investigation Plan or requesting the Product-Specific Waiver
Children	All children, from birth to the day of the 18 th birthday.
Paediatric investigation plan (PIP)	Set of studies and measures, usually including clinical studies in children, to evaluate the benefits and the risks of the use of a medicine in children, for a given disease or condition. A PIP may include "partial" waivers (for example, for younger children) and/or a deferral (see below).
Waiver	An exemption from conducting studies in children, for a given disease or condition. This can be granted for all children (product-specific waiver), or in specific subsets (partial waiver): for example, in boys or in children below a given age.
Deferral	The possibility to request marketing authorisation for the use of the medicine in adults, before completing one or more of the studies /measures included in a PIP. The Paediatric Committee may grant a deferral to avoid a delay in the availability of the medicine for adults.
Opinion	The result of the evaluation by the Paediatric Committee of the European Medicines Agency. The opinion may grant a product-specific waiver, or agree a PIP.
Decision	The legal act issued by the European Medicines Agency, which puts into effect the Opinion of the Paediatric Committee.
Pharmaceutical form	The physical aspect of the medicine (the form in which it is presented), for example: a tablet, capsule, powder, solution for injection, etc. A medicine can have more than one pharmaceutical form.
Placebo	A substance that has no therapeutic effect, used as a control in testing new drugs.
Active control	A medicine with therapeutic effect, used as a control in testing new drugs.
Historical control	A group of patients with the same disease, treated in the past and used in a comparison with the patients treated with the new drug.
Route of administration	How a medicine is given to the patient. For example: for oral use, for intramuscular use, for intravenous use, etc. The same medicine, or the same pharmaceutical form, may be given through more than one route of administration.
Patent	A form of protection of intellectual property rights. If a medicinal product is protected by a patent, the patent holder has the sole right to make, use, and sell the product, for a limited period. In certain circumstances, a patent for a medicinal product may be extended for a variable period by a Supplementary Protection Certificate.
Marketing Authorisation	When a Marketing Authorisation is granted, the pharmaceutical company may start selling the medicine in the relevant country (in the whole European Union, if the procedure was a centralised one).